ZA201105033B - Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride - Google Patents

Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride

Info

Publication number
ZA201105033B
ZA201105033B ZA2011/05033A ZA201105033A ZA201105033B ZA 201105033 B ZA201105033 B ZA 201105033B ZA 2011/05033 A ZA2011/05033 A ZA 2011/05033A ZA 201105033 A ZA201105033 A ZA 201105033A ZA 201105033 B ZA201105033 B ZA 201105033B
Authority
ZA
South Africa
Prior art keywords
chloro
methyl
pyrazol
fluorophenyl
crystalline
Prior art date
Application number
ZA2011/05033A
Other languages
English (en)
Inventor
Pingyun Y Chen
Jeffrey Gaulding
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201105033(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ZA201105033B publication Critical patent/ZA201105033B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2011/05033A 2009-01-30 2011-07-08 Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride ZA201105033B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14849009P 2009-01-30 2009-01-30
PCT/US2010/022323 WO2010088331A1 (en) 2009-01-30 2010-01-28 Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride

Publications (1)

Publication Number Publication Date
ZA201105033B true ZA201105033B (en) 2012-03-28

Family

ID=42395995

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/05033A ZA201105033B (en) 2009-01-30 2011-07-08 Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride

Country Status (25)

Country Link
US (5) US20110288142A1 (enExample)
EP (2) EP4242206A1 (enExample)
JP (4) JP2012516344A (enExample)
KR (1) KR101420484B1 (enExample)
CN (1) CN102405047B (enExample)
AR (1) AR075153A1 (enExample)
AU (1) AU2010208265B2 (enExample)
BR (1) BRPI1006896B1 (enExample)
CA (1) CA2750565C (enExample)
CL (1) CL2011001830A1 (enExample)
CO (1) CO6400189A2 (enExample)
CR (1) CR20110422A (enExample)
EA (1) EA018907B1 (enExample)
IL (1) IL214023A (enExample)
MA (1) MA32998B1 (enExample)
MX (1) MX2011008073A (enExample)
MY (1) MY161598A (enExample)
NZ (1) NZ594064A (enExample)
PE (1) PE20120003A1 (enExample)
SG (1) SG172926A1 (enExample)
TW (1) TWI503317B (enExample)
UA (1) UA106740C2 (enExample)
UY (1) UY32407A (enExample)
WO (1) WO2010088331A1 (enExample)
ZA (1) ZA201105033B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1006896B1 (pt) * 2009-01-30 2022-05-24 Novartis Ag Cloridrato de n-{(1s)-2-amino-1-[(3-fluorfenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h- pirazol-5-il)-2-tiofenocarboxamida cristalino, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou diminuir a gravidade de câncer e artrite
US20130072507A1 (en) * 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
WO2011150044A1 (en) * 2010-05-26 2011-12-01 Glaxosmithkline Llc Combination
BR112013017722A2 (pt) * 2011-01-11 2016-07-12 Glaxosmithkline Llc combinação
WO2013160222A1 (en) * 2012-04-24 2013-10-31 Glaxosmithkline Intellectual Property (No. 2) Limited Treatment method for steroid responsive dermatoses
US20160051674A1 (en) * 2013-04-18 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ctps 1 inhibitors, e.g. norleucine) for inhibiting t cell proliferation in a subject in need thereof
KR101797415B1 (ko) * 2013-10-01 2017-11-13 노파르티스 아게 암의 치료를 위한 아푸레세르팁과 조합된 엔잘루타미드
BR112016006976A2 (pt) * 2013-10-01 2017-08-01 Novartis Ag combinação
RU2016139697A (ru) * 2014-03-12 2018-04-12 Новартис Аг Комбинация, содержащая ингибитор btk и ингибитор akt
NZ752443A (en) 2016-10-11 2022-11-25 Univ Duke Lasofoxifene treatment of er+ breast cancer
JP6515944B2 (ja) 2016-12-20 2019-05-22 株式会社デンソー 半導体装置およびその製造方法
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
MX2022001450A (es) 2019-08-08 2022-04-20 Laekna Ltd Metodo de tratamiento del cancer.
US11915283B1 (en) 2019-08-13 2024-02-27 Splitcart Llc Cost sharing platform and system
US12067592B2 (en) 2019-08-13 2024-08-20 Splitcart Llc Co-purchasing system and method
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2023174210A1 (en) 2022-03-14 2023-09-21 Laekna Limited Combination treatment for cancer

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE758350A (fr) * 1969-12-30 1971-05-03 Pfizer Procede de fabrication des sels mono- et bi-metalliques alcalins de l'alpha-carboxybenzylpenicilline
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
ES2005163A6 (es) 1987-04-14 1989-03-01 Lilly S A E Un procedimiento para la produccion de derivados de tiofen-2-carboxamida.
IE67334B1 (en) 1988-03-16 1996-03-20 Smithkline Beecham Farma Heterocyclic derivatives
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
US4999059A (en) * 1989-08-11 1991-03-12 Bagno Robert G Universal solar concentrator panel
DE3927483A1 (de) 1989-08-19 1991-02-21 Boehringer Ingelheim Kg Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
DE3933573A1 (de) 1989-10-07 1991-04-18 Basf Ag Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DE4233198A1 (de) * 1992-10-02 1994-04-07 Bayer Ag Substituierte Thiophencarbonsäureamide
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
WO1994008577A1 (en) 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH08502508A (ja) 1992-10-23 1996-03-19 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド
DK0690864T3 (da) * 1993-03-12 2001-09-17 Upjohn Co Krystallinsk ceftiofur på fri syreform
WO1995004729A1 (en) 1993-08-06 1995-02-16 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
USRE39088E1 (en) 1995-08-22 2006-05-02 Japan Tobacco, Inc. Amide compounds and use of the same
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
US5998336A (en) 1997-02-26 1999-12-07 The Board Of Trustees Of The Leland Stanford Junior University Ceramic/metal and A15/metal superconducting composite materials exploiting the superconducting proximity effect and method of making the same
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
DE19882893T1 (de) 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPP433398A0 (en) 1998-06-25 1998-07-16 Australian National University, The Compounds and processes
US6192967B1 (en) 1998-10-19 2001-02-27 Sunny En Liung Huang Collapsible auto shade
US6130333A (en) 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
DE19904396A1 (de) 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
DE19904397A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
SK14102001A3 (sk) 1999-04-13 2002-07-02 Basf Aktiengesellschaft Ligandy integrínového receptora
JP2003500386A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
CA2374641A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibitors of factor xa
JP2003507329A (ja) 1999-08-12 2003-02-25 フアルマシア・イタリア・エツセ・ピー・アー ３（５）−アミノ−ピラゾール誘導体、それらの製造方法および抗腫瘍薬としてのそれらの使用
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
AU6469401A (en) 2000-05-19 2001-11-26 Serono Reproductive Biology In Pharmaceutically active compounds and methods of use
US6589195B1 (en) * 2000-05-26 2003-07-08 Orthomerica Products, Inc. Modular adjustable prophylactic hip orthosis and adduction/abduction joint
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
US6624039B1 (en) * 2000-07-13 2003-09-23 Lucent Technologies Inc. Alignment mark having a protective oxide layer for use with shallow trench isolation
AU2001277143A1 (en) 2000-07-24 2002-02-05 Davide Riccardo Grassetti Inhibition of mutagenic effects of carcinogens
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JP4267920B2 (ja) 2001-01-26 2009-05-27 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
EP1390353A1 (en) 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
JP4342939B2 (ja) 2001-08-03 2009-10-14 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターおよびその使用
ATE392421T1 (de) 2001-08-03 2008-05-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
WO2003026572A2 (en) * 2001-09-26 2003-04-03 Merck & Co., Inc. Crystalline forms of ertapenem sodium
US20040198799A1 (en) 2001-09-27 2004-10-07 Brondyk William H. Methods of increasing endogenous testosterone levels
US6794252B2 (en) * 2001-09-28 2004-09-21 Texas Instruments Incorporated Method and system for forming dual work function gate electrodes in a semiconductor device
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2003039529A1 (en) 2001-11-07 2003-05-15 4Sc A.G. Selective antibacterial agents
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
MXPA04007697A (es) 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
US7335779B2 (en) 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US20050154202A1 (en) 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
GB0216224D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
AU2003265348B2 (en) 2002-08-08 2007-08-16 Smithkline Beecham Corporation Thiophene compounds
NZ538339A (en) 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
KR20050038631A (ko) 2002-08-23 2005-04-27 카이론 코포레이션 글리코겐 신타제 키나제 3의 피롤 기제 억제제
JP2006517211A (ja) 2003-02-10 2006-07-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト Ｐｇｉ２アンタゴニストとして使用するためのビス（ヘテロ）アリールカルボキサミド誘導体
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US7517887B2 (en) 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
EP1615892A2 (en) 2003-04-21 2006-01-18 Elan Pharmaceuticals, Inc. Benzamide 2-hydroxy-3-diaminoalkanes
RU2401836C2 (ru) 2003-06-20 2010-10-20 Галдерма Ресерч энд Девелопмент, С.Н.С. НОВЫЕ СОЕДИНЕНИЯ, КОТОРЫЕ МОДУЛИРУЮТ РЕЦЕПТОРЫ ТИПА PPARγ, И ИХ ПРИМЕНЕНИЕ В КОСМЕТИЧЕСКИХ И ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЯХ
FR2857666B1 (fr) 2003-07-15 2005-08-26 Oreal Composition tinctoriale comprenant a titre de coupleur un derive du furane et nouveaux derives du furane
DK1651232T3 (da) 2003-07-23 2011-02-28 Synta Pharmaceuticals Corp Forbindelser mod inflammation og immunrelaterede anvendelser
DE602004012578T2 (de) 2003-08-15 2008-12-11 Vertex Pharmaceuticals Inc., Cambridge Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
EP1670466A4 (en) 2003-10-06 2007-04-25 Glaxo Group Ltd PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
WO2005037198A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
AU2004291147A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
JP2007512364A (ja) 2003-11-21 2007-05-17 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼインヒビター
US20050145202A1 (en) * 2004-01-05 2005-07-07 James Bonner Rigid dog leash
EP1706159B1 (en) 2004-01-19 2013-06-26 Atul Kumar A system for distending body tissue cavities by continuous flow irrigation
AR047894A1 (es) 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
CA2560691A1 (en) * 2004-03-24 2005-10-13 Abbott Laboratories Tricyclic pyrazole kinase inhibitors
EP1732919A1 (en) 2004-03-30 2006-12-20 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2005336172A (ja) 2004-04-26 2005-12-08 Japan Tobacco Inc 腎虚血再灌流障害治療又は予防薬
AU2005247610A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Substituted thiazoleacetic as crth2 ligands
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
JP2006066488A (ja) * 2004-08-25 2006-03-09 Mitsubishi Electric Corp 半導体受光素子およびその製造方法
US7365385B2 (en) * 2004-08-30 2008-04-29 Micron Technology, Inc. DRAM layout with vertical FETs and method of formation
US20060043513A1 (en) * 2004-09-02 2006-03-02 Deok-Hoon Kim Method of making camera module in wafer level
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20060062453A1 (en) * 2004-09-23 2006-03-23 Sharp Laboratories Of America, Inc. Color highlighting document image processing
WO2006040649A1 (en) * 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CN101044144A (zh) 2004-11-30 2007-09-26 神经研究公司 作为胆碱能配体的新的二氮杂双环芳基衍生物
JP2006232707A (ja) 2005-02-23 2006-09-07 Japan Tobacco Inc 癌転移抑制剤
US20060252807A1 (en) 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
US20060288588A1 (en) 2005-06-22 2006-12-28 Frank Morabito Garden tool
AU2006261132A1 (en) 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
EP1910308B1 (en) 2005-06-27 2014-09-03 Exelixis Patent Company LLC Imidazole based lxr modulators
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
JP2009521504A (ja) 2005-12-22 2009-06-04 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性阻害剤
JP5140600B2 (ja) 2005-12-23 2013-02-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー オーロラキナーゼのアザインドール阻害薬
JP5503874B2 (ja) 2006-02-28 2014-05-28 ダート ニューロサイエンス （ケイマン） エルティーディー 治療化合物
JP2007277230A (ja) 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
EP1840114A1 (en) * 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
WO2007122686A1 (ja) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
US20080027044A1 (en) * 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
PE20080859A1 (es) * 2006-10-13 2008-09-04 Basf Ag Hidratos de 2-cloro-5-[3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil]-4-fluor-n-[[metil(1-metiletil)amino]sulfonil]benzamida
WO2008057775A2 (en) * 2006-10-27 2008-05-15 Bristol-Myers Squibb Company Heterocyclic amide compounds useful as kinase inhibitors
AU2007338689A1 (en) 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of C3a receptor and methods of use thereof
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
EP2114388B1 (en) 2007-02-07 2015-05-20 GlaxoSmithKline LLC Inhibitors of akt activity
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008121685A1 (en) 2007-03-28 2008-10-09 Smithkline Beecham Corporation Methods of use for inhibitors of akt activity
JP2010522770A (ja) 2007-03-29 2010-07-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害物質
BRPI1006896B1 (pt) 2009-01-30 2022-05-24 Novartis Ag Cloridrato de n-{(1s)-2-amino-1-[(3-fluorfenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h- pirazol-5-il)-2-tiofenocarboxamida cristalino, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou diminuir a gravidade de câncer e artrite
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
NZ594064A (en) 2012-08-31
CA2750565A1 (en) 2010-08-05
BRPI1006896B1 (pt) 2022-05-24
EA201101144A1 (ru) 2011-12-30
US20150045405A1 (en) 2015-02-12
AU2010208265A1 (en) 2011-08-04
CA2750565C (en) 2015-10-20
EA018907B1 (ru) 2013-11-29
CR20110422A (es) 2011-09-22
SG172926A1 (en) 2011-08-29
IL214023A0 (en) 2011-08-31
CL2011001830A1 (es) 2012-04-09
PE20120003A1 (es) 2012-02-12
JP2012516344A (ja) 2012-07-19
JP6328590B2 (ja) 2018-05-23
BRPI1006896A2 (pt) 2020-08-18
MA32998B1 (fr) 2012-01-02
US8609711B2 (en) 2013-12-17
JP2019135237A (ja) 2019-08-15
CN102405047B (zh) 2014-07-09
EP4242206A1 (en) 2023-09-13
KR20110117127A (ko) 2011-10-26
EP2400964A4 (en) 2012-08-01
CN102405047A (zh) 2012-04-04
KR101420484B1 (ko) 2014-07-28
US20110288142A1 (en) 2011-11-24
EP2400964A1 (en) 2012-01-04
JP2017061559A (ja) 2017-03-30
TW201038564A (en) 2010-11-01
UY32407A (es) 2010-07-30
UA106740C2 (uk) 2014-10-10
US20100197754A1 (en) 2010-08-05
MX2011008073A (es) 2011-11-18
AU2010208265B2 (en) 2012-12-06
US20150353531A1 (en) 2015-12-10
CO6400189A2 (es) 2012-03-15
US20140073679A1 (en) 2014-03-13
JP2015212269A (ja) 2015-11-26
IL214023A (en) 2014-08-31
MY161598A (en) 2017-04-28
AR075153A1 (es) 2011-03-16
JP6924794B2 (ja) 2021-08-25
WO2010088331A1 (en) 2010-08-05
TWI503317B (zh) 2015-10-11

Similar Documents

Publication Publication Date Title
ZA201105033B (en) Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
GB2485688B (en) Cavity antennas for electronic devices
LT2459176T (lt) Kristalizacijos būdas ir bioprieinamumas
ZA201108349B (en) Thiophene derivatives
EP2422559A4 (en) WIRELESS SYNCHRONIZATION MECHANISM
IL200647A0 (en) Method for producing high purity prasugrel hydrochloride
SG10201610626PA (en) Polymorphic form of rotigotine
EP2435439B8 (en) Preparation of nalmefene hydrochloride from naltrexone
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
LT2448968T (lt) Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
PL2571823T3 (pl) Komórkowa forma do gięcia
GB2469899B (en) Primary piston correction during transfer
IL213714A0 (en) Process for preparing cinacalcet hydrochloride
PL2477964T3 (pl) Proces wytwarzania pochodnych alfa-karboksyamidu
PL2301943T3 (pl) Krystalizacja epidaunorubicyny x HCI
ZA201109041B (en) Novel cyclopentane derivatives
ZA201106443B (en) Flavanoid compounds and process for preparation thereof
IL214858A (en) Process for preparation of antiviral compound
EP2016066A4 (en) PROCESS FOR PREPARING DULOXETINE
IL207607A (en) Process for the production of a yarn compound and its intermediate
EP2507212A4 (en) PROCESS FOR PREPARING METHYLPHENIDATE HYDROCHLORIDE
GB0900198D0 (en) Ammoximation process
HK1164712A (en) Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
PL2628740T3 (pl) Sposób wytwarzania chlorowodorku (6r)-tetrahydrobiopteryny